Inotersen vs placebo
QoL · people with TTR‐FAP
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 172 participantsLow
Findings
What do systematic reviews say?
807 questions · 849 findings · 68 reviews · Headline outcomes only
No studies found 236 · 27.8%GRADE not reported 50 · 5.9%Very low 266 · 31.3%Low 168 · 19.8%Moderate 104 · 12.2%High 25 · 2.9%
Inotersen vs placebo
Has died · people with TTR‐FAP
Inotersen showed no clear difference in number of participants who died during the trial compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 5.94 [0.33, 105.6]1 study · 172 participantsLow
Inotersen vs placebo
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 8.57 [1.16, 63.07]1 study · 172 participantsLow
Inotersen vs placebo
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
Inotersen showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 1.48 [0.85, 2.57]1 study · 172 participantsLow
Tafamidis vs placebo
QoL · people with early‐stage TTR‐FAP
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 125 participantsVery low
Tafamidis vs placebo
Has died · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 0.65 [0.11, 3.74]1 study · 128 participantsVery low
Tafamidis vs placebo
Withdrawals due to adverse events · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 1.29 [0.3, 5.54]1 study · 128 participantsVery low
Tafamidis vs placebo
Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 1.16 [0.37, 3.62]1 study · 128 participantsVery low
Diflunisal vs placebo
Disability due to FAP progression (expressed as the change in Kumamoto Score) Scale from: 0 (normal) to 102 (worst disease severity). · people with TTR‐FAP
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 130 participantsLow
Diflunisal vs placebo
Severity of peripheral neuropathy (expressed as the change in NIS+7) Scale from: 0 (normal) to 270 (total impairment) · people with TTR‐FAP
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 130 participantsLow
Diflunisal vs placebo
Physical quality of life · people with TTR‐FAP
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 130 participantsVery low
Intervention not reported
Typical antipsychotic vs placebo · critically ill adults with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 608 participantsHigh
Intervention not reported
Typical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 515 participantsModerate
Intervention not reported
Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 476 participantsModerate
Intervention not reported
Statin (HMG‐CoA)vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 272 participantsModerate
Intervention not reported
Alpha2 agonist vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 71 participantsModerate
Intervention not reported
Opioid vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsVery low
Intervention not reported
Typical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 618 participantsModerate
Intervention not reported
Atypical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 577 participantsHigh
Intervention not reported
Statin (HMG‐CoA) vs placebo · critically ill adult with confirmed or at high risk of delirium
1 finding from 1 review
- Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 272 participantsLow